Merck & Co., Inc.

🇺🇸New York Stock Exchange
Back to all articles
Merck & Co., Inc. stock analysis MRK overview
Somewhat Bullish +50

Dow Jones' Merck Tops Forecasts, But There Are Nuances - Investor's Business Daily

📈 Merck reported Q1 earnings that beat Wall Street forecasts with a narrower-than-expected per-share loss of $1.28 versus the projected $1.47.

💊 Revenue from blockbuster cancer drug Keytruda reached $8.03 billion, a 12% increase driven by strong performance of the new Qlex formulation.

📉 Despite solid sales, Merck's stock slipped 1.6% to $109.18 following the earnings release.

💼 Total company sales grew 5% year-over-year to $16.3 billion, exceeding analyst estimates of $15.85 billion.

🚨 Management narrowed its full-year sales guidance slightly, raising the midpoint range to $65.8–$67 billion compared to previous projections.

⚠️ Analyst Daina Graybosch from Leerink Partners highlighted Keytruda's looming patent expiration in 2032 as a key risk factor for future growth.

🧬 Qlex is expected to be difficult for biosimilar substitution, protecting Merck's market share and reimbursement status against generic competitors.

🌬️ Revenue from acquired COPD drug Ohtuvayre missed forecasts at $131 million compared to the anticipated $158 million.

🩺 Conversely, Winrevair sales surged 88% to $525 million, significantly smashing the Street's forecast of $499 million for the high blood pressure treatment.

💰 Both Ohtuvayre and Winrevair are major growth drivers originating from large acquisitions: Acceleron Pharma (2021) and Verona Pharma (2025).

📅 Graybosch noted that continued business development is crucial to offsetting potential revenue declines once Keytruda loses exclusivity.

🔬 The company has a strong pipeline of late-stage assets focused on cancer and immunological conditions with pivotal readouts expected in the coming quarters.

⚡ Merck's Animal Health segment showed strength, helping to balance out weakness seen in the vaccine division.

💵 Adjusted earnings guidance for the year is set between $5.04 and $5.16 per share.

🔍 The current financial guidance does not include accounting charges related to the planned acquisition of Terns Pharmaceuticals.

Bullish Signals
  • Keytruda delivered $8.03 billion in sales, a strong 12% increase that handily beat Wall Street forecasts.
  • Keytruda Qlex contributed $128 million in its second full quarter on the market while receiving approval expansions for ovarian cancer and multiple tumor types.
  • Winrevair revenue exceeded analyst expectations, growing 88% to $525 million against a forecast of $499 million.
  • Merck's total sales grew 5% to $16.3 billion, significantly topping the $15.85 billion consensus estimate.
  • The company reported a per-share loss of $1.28, which improved upon analyst projections of a $1.47 loss.
  • Management raised its full-year sales guidance midpoint to $67 billion, signaling confidence in future growth potential.
  • Analyst Daina Graybosch highlighted that continued business development could significantly improve growth prospects ahead of Keytruda's patent expiration in 2032.
Risk Factors
  • Merck stock slipped 1.6% to $109.18 immediately following the earnings report, indicating investor caution despite beating forecasts.
  • Keytruda will lose patent protection after 2032, a looming expiration that requires novel combinations or business development to mitigate growth risks.
  • Ohtuvayre sales of $131 million fell short of the $158 million forecast, contributing to weakness in the broader portfolio despite strong results elsewhere.
  • Merck is planning a one-time charge of $2.35 per share related to the planned acquisition of Terns Pharmaceuticals (TERN).
  • The company narrowed its guidance for the year, with sales expectations ranging from $65.8 billion to $67 billion.
  • Analysts suggest that without continued business development, growth prospects could be negatively impacted by Keytruda's loss of exclusivity.
Full Analysis
Dow Jones' Merck (MRK) surpassed Wall Street expectations on Wednesday by reporting lighter-than-anticipated losses, driven significantly by strong performance from its flagship cancer drug, Keytruda. The blockbuster medication generated $8.03 billion in sales, representing a 12% increase overall or an 8% rise when excluding currency fluctuations. This revenue included contributions from Keytruda Qlex, an under-the-skin injection that contributed $128 million during its second full quarter of market availability. Despite these positive results, Merck's stock price slipped 1.6% to close at $109.18. The company is actively pursuing label expansions for Keytruda Qlex, noting two approvals for ovarian cancer and additional approvals for multiple tumor types within the reporting quarter. Analyst Daina Graybosch of Leerink Partners highlighted that while finding novel combinations with Keytruda Qlex could help manage the upcoming patent expiration expected around 2032, the company's broader portfolio remains a critical growth engine. She specifically identified Ohtuvayre and Winrevair as key drivers. Ohtuvayre, used for chronic obstructive pulmonary disease (COPD), generated $131 million in first-quarter sales, missing the $158 million forecast. In contrast, Winrevair, a treatment for pulmonary hypertension acquired from Acceleron Pharma in a 2021 deal worth $11.5 billion, exceeded forecasts with $525 million in revenue, an 88% increase on an as-reported basis against a Street expectation of $499 million. Merck also recently acquired Verona Pharma, the maker of Ohtuvayre, for $10 billion in 2025. On a consolidated basis, Merck's total sales grew 5% to $16.3 billion, or 3% on a constant currency basis, easily beating the consensus estimate of $15.85 billion. The company reported a per-share loss of $1.28, which was an improvement over the projected loss of $1.47 per share. Consequently, Merck narrowed its full-year sales guidance to a range of $65.8 billion to $67 billion, noting that this range includes a higher midpoint than previously indicated three months ago. Additionally, the company projects adjusted earnings between $5.04 and $5.16 per share for the year. This guidance excludes the anticipated one-time charge of $2.35 per share associated with the planned acquisition of Terns Pharmaceuticals (TERN). Analyst Graybosch concluded that while continued business development would significantly improve growth prospects beyond Keytruda's loss of exclusivity, the current late-stage pipeline assets provide a strong commercial foundation.